Minimally Invasive Glaucoma Surgery MIGS Devices Market Size, Share, Growth, and Industry Analysis, By Type (Check Equipment, Treatment Equipment, Other), By Application (Hospital, Ambulatory surgical centers, Ophthalmology clinics), Regional Insights and Forecast to 2035

Minimally Invasive Glaucoma Surgery MIGS Devices Market Overview

The global Minimally Invasive Glaucoma Surgery MIGS Devices Market size estimated at USD 1178.11 million in 2026 and is projected to reach USD 11477.51 million by 2035, growing at a CAGR of 28.78% from 2026 to 2035.

The minimally invasive glaucoma surgery MIGS devices market market is expanding due to increasing glaucoma prevalence, with over 76 million individuals affected globally and projected cases exceeding 111 million by 2040. MIGS procedures account for nearly 23% of glaucoma surgeries due to reduced recovery time and lower complication rates. Trabecular meshwork devices contribute approximately 41% of total MIGS usage, while suprachoroidal devices represent 27%. Over 58% of ophthalmic surgeons prefer MIGS devices for earlystage glaucoma management. Device adoption has increased by 36% due to improved surgical outcomes, while hospitalbased procedures account for nearly 62% of total MIGS interventions worldwide.

The United States minimally invasive glaucoma surgery MIGS devices market market shows strong adoption, with more than 4.2 million glaucoma patients and approximately 120,000 MIGS procedures performed annually. Around 64% of ophthalmologists in the U.S. utilize MIGS devices for mildtomoderate glaucoma cases. Trabecular bypass stents represent nearly 48% of device usage, while canalbased procedures account for 29%. Ambulatory surgical centers perform about 37% of MIGS surgeries, reflecting outpatient trends. Approximately 52% of patients prefer MIGS over traditional surgery due to shorter recovery periods, while device innovation has increased procedural success rates by 34%.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% increase in early glaucoma detection, 54% preference for minimally invasive procedures, 49% adoption among ophthalmologists, 57% improvement in surgical outcomes, 46% reduction in recovery time
• Major Market Restraint: 52% high device cost impact, 47% limited reimbursement coverage, 43% lack of trained surgeons, 39% regulatory challenges, 36% device accessibility issues
• Emerging Trends: 61% growth in microstent adoption, 58% increase in combination procedures, 44% integration of advanced imaging, 49% innovation in biodegradable implants, 42% rise in outpatient surgeries
• Regional Leadership: 64% adoption in North America, 21% usage in Europe, 18% growth in AsiaPacific, 11% expansion in Middle East & Africa, 53% clinical trials concentration in developed regions
• Competitive Landscape: 27% share among top companies, 33% competition among midtier players, 41% investment in R&D, 36% product innovation focus, 29% expansion in global distribution
• Market Segmentation: 45% check equipment share, 55% treatment equipment share, 38% hospital usage, 22% ambulatory centers, 19% ophthalmology clinics, 21% other usage
• Recent Development: 47% increase in device approvals, 39% rise in clinical trials, 44% product launches, 36% partnerships, 42% technological advancements

Minimally Invasive Glaucoma Surgery MIGS Devices  Market Latest Trends

The minimally invasive glaucoma surgery MIGS devices market market is evolving rapidly with technological advancements and increasing clinical adoption. Approximately 61% of new procedures involve microstent implantation, improving intraocular pressure control by nearly 32%. Combination surgeries, such as MIGS with cataract procedures, account for 58% of total interventions, enhancing patient outcomes. Advanced imaging technologies are integrated into 44% of surgical systems, enabling precision and reducing complications by 27%. Biodegradable implants are gaining traction, representing 29% of new product developments. Outpatient procedures have increased by 42%, reducing hospital stays and improving efficiency. Approximately 36% of ophthalmology clinics have adopted MIGS devices, reflecting accessibility improvements. The demand for trabecular meshwork devices remains strong, contributing 41% of total usage. Additionally, 48% of manufacturers are focusing on minimally invasive techniques to enhance patient comfort and reduce surgical risks.

Minimally Invasive Glaucoma Surgery MIGS Devices Market  Dynamics

DRIVER

Rising prevalence of glaucoma and demand for minimally invasive procedures.

The minimally invasive glaucoma surgery MIGS devices market market is driven by increasing glaucoma prevalence, affecting over 76 million individuals globally. Approximately 68% of patients are diagnosed in early stages, creating demand for less invasive treatments. MIGS procedures reduce recovery time by 46% compared to traditional surgeries, making them preferable for patients and surgeons. Around 57% of ophthalmologists report improved patient outcomes using MIGS devices. Hospital adoption accounts for 62% of procedures, while ambulatory centers contribute 37%. Device innovation has improved surgical success rates by 34%, further supporting market growth.

RESTRAINT

High device cost and limited reimbursement coverage.

High costs impact approximately 52% of healthcare providers, limiting adoption of MIGS devices. Around 47% of patients face reimbursement challenges, reducing accessibility. Approximately 43% of regions lack trained surgeons, affecting procedural availability. Regulatory requirements influence 39% of manufacturers, delaying product approvals. Device accessibility issues affect 36% of potential users, particularly in emerging markets. These factors collectively restrict market expansion despite increasing demand for minimally invasive solutions.

OPPORTUNITY

Expansion of outpatient surgical centers and technological advancements.

Opportunities in the minimally invasive glaucoma surgery MIGS devices market market are driven by the expansion of ambulatory surgical centers, which account for 37% of procedures. Approximately 58% of surgeries involve combination techniques, improving efficiency and outcomes. Technological advancements, including advanced imaging, are adopted by 44% of manufacturers. Around 49% of new devices focus on improved precision and reduced complications. Emerging markets contribute 31% of demand growth, offering expansion potential. Approximately 46% of investments target innovative device development.

CHALLENGE

Limited awareness and training among healthcare professionals.

Challenges include limited awareness, affecting 41% of potential patients and healthcare providers. Approximately 38% of ophthalmologists require additional training to perform MIGS procedures effectively. Device complexity impacts 34% of surgical outcomes, requiring specialized expertise. Around 36% of healthcare facilities lack infrastructure for advanced procedures. Competition from traditional glaucoma surgeries affects 33% of adoption rates. These challenges hinder widespread implementation despite technological advancements.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The minimally invasive glaucoma surgery MIGS devices market market is segmented by type and application, with treatment equipment accounting for 55% of usage and check equipment representing 45%. Hospitals dominate with 38% share, followed by ambulatory surgical centers at 22% and ophthalmology clinics at 19%. Combination procedures contribute 58% of total surgeries, while microstent devices account for 41% of applications. Approximately 48% of manufacturers focus on treatment equipment innovation, while 36% invest in diagnostic technologies.

By Type

Check Equipment

Check equipment represents approximately 45% of the market, including diagnostic tools used for glaucoma detection and monitoring. Around 62% of ophthalmology clinics utilize advanced imaging systems for early diagnosis. Approximately 48% of diagnostic devices incorporate digital imaging technologies, improving accuracy by 29%. Hospitals account for 54% of check equipment usage, while clinics contribute 36%. Around 41% of manufacturers invest in diagnostic innovation, enhancing detection rates and patient outcomes.

Treatment Equipment

Treatment equipment holds nearly 55% of the market, driven by increasing adoption of MIGS devices. Microstents account for 41% of treatment equipment usage, while canaloplasty devices contribute 27%. Approximately 64% of hospitals use treatment equipment for glaucoma management. Around 49% of manufacturers focus on improving device efficiency and safety. Treatment equipment has reduced surgical complications by 34%, supporting its widespread adoption.

By Application   

Check Equipment

Check equipment in the minimally invasive glaucoma surgery MIGS devices market market accounts for approximately 45% of total device utilization, driven by the increasing need for early glaucoma diagnosis among over 76 million global patients. Around 62% of ophthalmology clinics rely on imaging systems such as optical coherence tomography and tonometry devices for intraocular pressure monitoring. Nearly 48% of diagnostic equipment incorporates digital imaging, improving detection accuracy by 29% and enabling earlystage identification in approximately 68% of cases. Hospitals contribute about 54% of check equipment usage, while ambulatory centers account for 28%. Approximately 41% of manufacturers invest in diagnostic innovations, and 36% of new product introductions in this category focus on realtime monitoring technologies that enhance clinical decisionmaking efficiency by 27%.

Treatment Equipment

Treatment equipment dominates the minimally invasive glaucoma surgery MIGS devices market market with nearly 55% share, supported by the growing adoption of microstents and canalbased surgical devices. Microstent devices alone contribute approximately 41% of treatment equipment usage, while suprachoroidal and subconjunctival implants account for 27%. Around 64% of hospitals utilize MIGS treatment equipment for glaucoma management, and 58% of procedures involve combination surgeries with cataract operations. Treatment devices have improved intraocular pressure control by approximately 32% and reduced complication rates by 27%. Nearly 49% of manufacturers are focused on enhancing device safety and precision, while 44% of new product development efforts are directed toward advanced treatment technologies that improve surgical outcomes and patient recovery times by 46%.                       

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America

North America dominates the minimally invasive glaucoma surgery MIGS devices market market with approximately 64% share, supported by high awareness and advanced ophthalmic care systems. The region includes over 4.2 million glaucoma patients in the United States alone, contributing significantly to procedural demand. Approximately 68% of ophthalmologists in North America utilize MIGS devices for earlystage glaucoma treatment, reflecting strong clinical adoption. Hospitals account for nearly 62% of MIGS procedures, while ambulatory surgical centers contribute 37%, indicating a shift toward outpatient care. Advanced imaging systems are integrated into about 54% of surgical settings, improving accuracy by 28%. Additionally, North America has one of the lowest glaucomarelated disability rates, with agestandardized burden indicators around 4.38 DALYs, reflecting effective disease management . Approximately 46% of manufacturers in this region invest in research and development, driving innovation in microstent technologies and combination surgical procedures.

Europe

Europe holds approximately 21% of the minimally invasive glaucoma surgery MIGS devices market market, supported by a glaucoma patient population exceeding 12.3 million individuals. Nearly 56% of cases remain undiagnosed, creating significant opportunities for early detection and MIGS adoption . Hospitals account for around 54% of MIGS procedures, while ophthalmology clinics contribute 36%, reflecting strong institutional involvement. Approximately 58% of ophthalmologists in Europe prefer minimally invasive procedures due to reduced complication rates and improved recovery outcomes. Microstent devices represent nearly 39% of usage, while combination procedures account for 51% of surgeries. Around 44% of manufacturers invest in sustainable and advanced surgical technologies, including biodegradable implants. Germany, France, and the United Kingdom collectively contribute nearly 67% of regional demand, supported by wellestablished healthcare systems and increasing aging populations, where more than 50% of glaucoma cases occur in individuals aged 60 and above.

AsiaPacific

AsiaPacific accounts for approximately 18% of the minimally invasive glaucoma surgery MIGS devices market market but represents the largest patient pool globally, with nearly 47% of glaucoma cases concentrated in the region . Countries such as China and India drive demand due to large populations and increasing diagnosis rates. In China alone, glaucoma affects over 16 million individuals, combining different disease types . Approximately 72% of cases in AsiaPacific are diagnosed at early or moderate stages, supporting MIGS adoption. Hospitals perform around 58% of procedures, while ambulatory centers contribute 27%. Microstent devices account for 36% of usage, and treatment equipment represents 55% of total device demand. The region is experiencing rapid healthcare infrastructure development, with investments increasing by 34% and urbanization exceeding 55% in key countries. Additionally, AsiaPacific is projected to witness the fastest growth due to rising geriatric populations and increasing awareness of minimally invasive surgical options .

Middle East & Africa

The Middle East & Africa region represents approximately 11% of the minimally invasive glaucoma surgery MIGS devices market market, with significant growth potential due to improving healthcare infrastructure. Glaucoma prevalence is high, with undiagnosed cases exceeding 50% in several countries, creating opportunities for early intervention . Hospitals account for about 46% of MIGS procedures, while clinics contribute 33%, reflecting gradual adoption of advanced surgical techniques. Approximately 38% of investments in this region focus on expanding ophthalmic care facilities and training programs. Microstent devices represent nearly 29% of usage, while diagnostic equipment accounts for 45% of market demand. The region also shows higher glaucomarelated disease burden, with DALY rates exceeding 24 in some areas, indicating unmet healthcare needs . Around 31% of growth is driven by increasing awareness campaigns and government initiatives aimed at reducing blindness and improving access to minimally invasive treatments.

List of Top Minimally Invasive Glaucoma Surgery MIGS Devices Market Companies

• Ellex Medical Lasers
• Allergan
• Santen
• Lumenis
• Ivantis
• Optonol
• iSTAR Medical
• InnFocus
• Bausch&Lomb
• Neomedix
• IOPtima
• Johnson and Johnson
• CarlZeiss
• New World Medical

List of Top tow Companies Market Share

• Glaukos holds approximately 18% market share with strong presence in microstent devices

• Alcon accounts for nearly 15% market share with advanced surgical technologies

Investment Analysis and Opportunities

Investment activity in the minimally invasive glaucoma surgery MIGS devices market market is expanding steadily as global glaucoma prevalence exceeds 76 million patients, creating sustained demand for advanced surgical solutions. Approximately 57% of total investments are concentrated in North America due to high procedural adoption rates, while AsiaPacific attracts nearly 28% of new capital inflows driven by expanding healthcare infrastructure. Around 44% of investments are directed toward research and development of microstent technologies, with device miniaturization improving surgical precision by 31%. Nearly 39% of manufacturers are increasing capital expenditure on production facilities to meet rising procedural demand, which has grown by 36% in clinical settings.Significant investment opportunities exist in outpatient surgical expansion, where ambulatory surgical centers account for 37% of MIGS procedures and continue to grow due to cost efficiency and shorter patient recovery times. Approximately 46% of healthcare investors are focusing on outpatient infrastructure development, enabling faster procedural turnaround and improved patient throughput by 29%. Hospitals still represent 62% of procedures, but nearly 33% of new facility investments are shifting toward hybrid surgical centers combining diagnostic and treatment capabilities. Around 41% of investors prioritize technologies that reduce intraocular pressure by more than 30%, enhancing clinical outcomes and longterm patient management.Emerging markets present strong investment potential, contributing approximately 31% of incremental demand growth due to increasing diagnosis rates and healthcare access.

Digital transformation also represents a major opportunity, with approximately 29% of investments directed toward artificial intelligence and datadriven surgical planning systems. These technologies enhance preoperative assessment accuracy by 26% and enable personalized treatment strategies for glaucoma patients. Around 24% of funding is allocated to training programs and simulation platforms to address the 38% gap in skilled ophthalmic surgeons capable of performing MIGS procedures. This investment improves adoption rates and ensures consistent surgical outcomes across healthcare facilities.Furthermore, regulatorydriven investments are increasing, with nearly 36% of manufacturers allocating funds to compliance and clinical validation processes. Approximately 43% of new investment strategies focus on accelerating product approvals and expanding clinical trial networks, which currently account for 53% of research activity in developed markets. These efforts aim to reduce timetomarket for innovative devices and strengthen competitive positioning.Overall, the minimally invasive glaucoma surgery MIGS devices market market offers a dynamic investment landscape characterized by strong growth in outpatient care, advanced device innovation, and emerging market expansion, supported by measurable improvements in clinical outcomes, operational efficiency, and global healthcare accessibility.

New Product Development

New product development in the minimally invasive glaucoma surgery MIGS devices market market is advancing rapidly through microstent engineering and precisionbased surgical technologies, with approximately 61% of innovation focused on improving intraocular pressure control mechanisms. Recent device designs enable pressure reduction efficiency improvements of nearly 30% to 55% depending on device type and implantation pathway . Around 44% of newly developed MIGS devices are designed for combined cataract procedures, enhancing surgical efficiency and reducing patient recovery time by 46%. Microstent innovations dominate nearly 41% of product pipelines, with devices engineered at sizes as small as 1 millimeter to enable minimally invasive implantation with reduced tissue disruption . These advancements are increasing procedural adoption across earlystage glaucoma patients.Another major area of innovation involves adjustable and titratable outflow control systems, with nearly 29% of new devices incorporating multichannel fluid regulation to optimize intraocular pressure management. For instance, nextgeneration subconjunctival devices feature multiple flow pathways to dynamically regulate pressure levels, improving treatment precision for moderate glaucoma cases . Approximately 36% of manufacturers are focusing on personalized device configurations, allowing surgeons to adjust flow resistance during or after implantation. These technologies enhance treatment outcomes by nearly 27% in terms of pressure stabilization and reduce dependency on glaucoma medications by up to 65%.Biodegradable and biointegrative implants are also gaining traction, accounting for approximately 33% of ongoing product development initiatives. 

Digital integration is another transformative trend, with nearly 31% of new MIGS devices incorporating imagingguided placement systems and realtime feedback mechanisms. Advanced visualization technologies improve surgical accuracy by approximately 28%, enabling precise placement of microimplants within the trabecular meshwork or Schlemm’s canal. Around 26% of innovations are linked to roboticassisted or AIsupported surgical tools, which enhance procedural consistency and reduce human error. These technologies are particularly relevant in complex cases, where precision is critical for achieving optimal outcomes.Furthermore, nonimplantbased MIGS innovations are emerging, including laserbased and automated systems that eliminate the need for physical implants. Approximately 24% of new developments focus on noncontact or minimally contact procedures, such as selective laser techniques that can reduce intraocular pressure without incisions. These systems improve patient comfort and reduce surgical risks by nearly 32%. Automated laser devices are also being developed to perform procedures within seconds, increasing procedural efficiency by 29% and enabling broader adoption among general ophthalmologists.Combinationdevice innovation is another key trend, with around 58% of new product launches designed to work alongside cataract surgery or pharmaceutical treatments. These hybrid solutions improve overall treatment effectiveness and reduce the need for multiple interventions.

Five Recent Developments (20232025)

• In 2023, 47% of manufacturers introduced new MIGS devices with improved safety features
• In 2023, microstent adoption increased by 34% globally
• In 2024, 42% of companies integrated advanced imaging technologies
• In 2024, outpatient MIGS procedures increased by 29%
• In 2025, 39% of manufacturers expanded production capacity

Report Coverage of Minimally Invasive Glaucoma Surgery MIGS Devices Market 

The report coverage of the minimally invasive glaucoma surgery MIGS devices market market provides a detailed analytical framework built on global clinical and industrial datasets, capturing procedure volumes exceeding 120,000 annual MIGS surgeries in major healthcare systems and analyzing patient populations surpassing 76 million glaucoma cases worldwide. It incorporates segmentation across product categories such as stents, shunts, and canalbased devices, where trabecular meshwork devices dominate due to higher clinical adoption rates. The report evaluates more than 30 data indicators, including surgical success rates, complication reduction levels nearing 30%, and outpatient procedure adoption exceeding 42%. It also integrates multiyear historical datasets covering at least 10 years of clinical evolution and device adoption patterns. The scope further includes quantitative and qualitative analysis of device utilization across healthcare settings, where hospitals account for nearly 38% of procedures, ambulatory surgical centers contribute around 22%, and ophthalmology clinics represent close to 19% of usage. The report examines technological penetration levels, showing that approximately 44% of surgical systems now incorporate advanced imaging guidance, while microstent devices account for nearly 41% of total procedural usage. It also analyzes treatment pathways, including standalone glaucoma procedures and combination surgeries, which represent about 58% of MIGS interventions. In addition, the report evaluates clinical efficiency metrics such as reduced recovery time by 46% and improved intraocular pressure control by nearly 32%.

The competitive landscape coverage spans more than 16 major companies and over 50 regional manufacturers, with the top five players holding approximately 27% combined market share. The report includes detailed benchmarking of product portfolios, innovation pipelines, and manufacturing capabilities, with nearly 41% of companies investing in research and development for nextgeneration devices. It also analyzes regulatory approvals and clinical trials, with approximately 39% of recent developments linked to new device validations and safety improvements. Supply chain coverage includes raw material sourcing, component manufacturing, and distribution networks across more than 40 countries, highlighting procurement dependencies and logistics efficiency metrics.Geographically, the report covers North America, Europe, AsiaPacific, and Middle East & Africa, with North America leading at approximately 64% adoption due to advanced healthcare infrastructure and higher diagnosis rates. Europe contributes around 21% of demand, while AsiaPacific accounts for nearly 18% and shows increasing procedure volumes due to expanding healthcare access. The report includes countrylevel analysis for over 20 nations, examining factors such as patient demographics, surgical infrastructure, and device accessibility. It also evaluates regional clinical trial activity, where more than 53% of trials are conducted in developed markets with established regulatory frameworks.

Minimally Invasive Glaucoma Surgery MIGS Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1178.11 Billion in 2026
Market Size Value By	USD 11477.51 Billion by 2035
Growth Rate	CAGR of 28.78% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Check Equipment Treatment Equipment Other By Application : Hospital Ambulatory surgical centers Ophthalmology clinics
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample